![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RNF167 |
Gene summary for RNF167 |
![]() |
Gene information | Species | Human | Gene symbol | RNF167 | Gene ID | 26001 |
Gene name | ring finger protein 167 | |
Gene Alias | 5730408C10Rik | |
Cytomap | 17p13.2 | |
Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q9H6Y7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26001 | RNF167 | C43 | Human | Oral cavity | OSCC | 1.93e-28 | 5.84e-01 | 0.1704 |
26001 | RNF167 | C46 | Human | Oral cavity | OSCC | 1.19e-20 | 5.79e-01 | 0.1673 |
26001 | RNF167 | C51 | Human | Oral cavity | OSCC | 9.72e-29 | 1.45e+00 | 0.2674 |
26001 | RNF167 | C57 | Human | Oral cavity | OSCC | 5.45e-12 | 5.71e-01 | 0.1679 |
26001 | RNF167 | C06 | Human | Oral cavity | OSCC | 1.39e-06 | 1.27e+00 | 0.2699 |
26001 | RNF167 | C07 | Human | Oral cavity | OSCC | 7.77e-08 | 1.71e+00 | 0.2491 |
26001 | RNF167 | C08 | Human | Oral cavity | OSCC | 1.19e-66 | 1.21e+00 | 0.1919 |
26001 | RNF167 | C09 | Human | Oral cavity | OSCC | 4.55e-13 | 5.25e-01 | 0.1431 |
26001 | RNF167 | LN22 | Human | Oral cavity | OSCC | 2.37e-18 | 1.74e+00 | 0.1733 |
26001 | RNF167 | LN46 | Human | Oral cavity | OSCC | 7.67e-07 | 4.58e-01 | 0.1666 |
26001 | RNF167 | LP15 | Human | Oral cavity | LP | 2.16e-17 | 1.94e+00 | 0.2174 |
26001 | RNF167 | LP17 | Human | Oral cavity | LP | 8.42e-10 | 1.34e+00 | 0.2349 |
26001 | RNF167 | SYSMH1 | Human | Oral cavity | OSCC | 1.13e-23 | 5.55e-01 | 0.1127 |
26001 | RNF167 | SYSMH2 | Human | Oral cavity | OSCC | 1.23e-22 | 6.36e-01 | 0.2326 |
26001 | RNF167 | SYSMH3 | Human | Oral cavity | OSCC | 2.72e-22 | 6.06e-01 | 0.2442 |
26001 | RNF167 | SYSMH4 | Human | Oral cavity | OSCC | 1.58e-06 | 1.01e-01 | 0.1226 |
26001 | RNF167 | SYSMH5 | Human | Oral cavity | OSCC | 3.38e-04 | 1.68e-01 | 0.0647 |
26001 | RNF167 | SYSMH6 | Human | Oral cavity | OSCC | 1.60e-13 | 4.23e-01 | 0.1275 |
26001 | RNF167 | P4_S8_cSCC | Human | Skin | cSCC | 1.77e-03 | 7.14e-02 | -0.3095 |
26001 | RNF167 | P1_cSCC | Human | Skin | cSCC | 1.72e-24 | 9.17e-01 | 0.0292 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0000209 | Colorectum | AD | protein polyubiquitination | 78/3918 | 236/18723 | 8.71e-06 | 2.06e-04 | 78 |
GO:00002091 | Colorectum | SER | protein polyubiquitination | 58/2897 | 236/18723 | 1.69e-04 | 3.18e-03 | 58 |
GO:00002092 | Colorectum | MSS | protein polyubiquitination | 72/3467 | 236/18723 | 5.19e-06 | 1.42e-04 | 72 |
GO:000020916 | Esophagus | HGIN | protein polyubiquitination | 58/2587 | 236/18723 | 6.29e-06 | 1.97e-04 | 58 |
GO:000020917 | Esophagus | ESCC | protein polyubiquitination | 170/8552 | 236/18723 | 1.40e-16 | 1.09e-14 | 170 |
GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
GO:000020911 | Liver | Cirrhotic | protein polyubiquitination | 89/4634 | 236/18723 | 6.09e-06 | 9.80e-05 | 89 |
GO:000020921 | Liver | HCC | protein polyubiquitination | 151/7958 | 236/18723 | 1.90e-11 | 7.59e-10 | 151 |
GO:0045786 | Liver | HCC | negative regulation of cell cycle | 204/7958 | 385/18723 | 1.84e-05 | 1.99e-04 | 204 |
GO:000020910 | Oral cavity | OSCC | protein polyubiquitination | 150/7305 | 236/18723 | 1.59e-14 | 9.27e-13 | 150 |
GO:00457864 | Oral cavity | OSCC | negative regulation of cell cycle | 206/7305 | 385/18723 | 4.28e-09 | 9.55e-08 | 206 |
GO:004578612 | Oral cavity | LP | negative regulation of cell cycle | 127/4623 | 385/18723 | 1.33e-04 | 1.53e-03 | 127 |
GO:000020915 | Oral cavity | LP | protein polyubiquitination | 82/4623 | 236/18723 | 3.23e-04 | 3.26e-03 | 82 |
GO:000020924 | Skin | cSCC | protein polyubiquitination | 103/4864 | 236/18723 | 2.57e-09 | 9.09e-08 | 103 |
GO:004578613 | Skin | cSCC | negative regulation of cell cycle | 140/4864 | 385/18723 | 3.64e-06 | 5.50e-05 | 140 |
GO:000020920 | Thyroid | PTC | protein polyubiquitination | 128/5968 | 236/18723 | 7.81e-13 | 3.65e-11 | 128 |
GO:00457867 | Thyroid | PTC | negative regulation of cell cycle | 166/5968 | 385/18723 | 1.93e-06 | 2.64e-05 | 166 |
GO:0000209110 | Thyroid | ATC | protein polyubiquitination | 134/6293 | 236/18723 | 1.86e-13 | 9.20e-12 | 134 |
GO:004578614 | Thyroid | ATC | negative regulation of cell cycle | 181/6293 | 385/18723 | 2.64e-08 | 5.07e-07 | 181 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RNF167 | SNV | Missense_Mutation | novel | c.916N>C | p.Glu306Gln | p.E306Q | Q9H6Y7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RNF167 | SNV | Missense_Mutation | rs754895476 | c.263N>A | p.Arg88Gln | p.R88Q | Q9H6Y7 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-C5-A2LV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RNF167 | SNV | Missense_Mutation | novel | c.80G>A | p.Arg27Gln | p.R27Q | Q9H6Y7 | protein_coding | tolerated(0.27) | probably_damaging(0.953) | TCGA-VS-A9UC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
RNF167 | SNV | Missense_Mutation | novel | c.203G>T | p.Ser68Ile | p.S68I | Q9H6Y7 | protein_coding | tolerated(0.14) | possibly_damaging(0.627) | TCGA-ZJ-AAX8-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
RNF167 | SNV | Missense_Mutation | c.802N>C | p.Cys268Arg | p.C268R | Q9H6Y7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
RNF167 | SNV | Missense_Mutation | c.241T>C | p.Ser81Pro | p.S81P | Q9H6Y7 | protein_coding | tolerated(0.08) | probably_damaging(0.959) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
RNF167 | SNV | Missense_Mutation | novel | c.299N>G | p.Asn100Ser | p.N100S | Q9H6Y7 | protein_coding | deleterious(0.03) | benign(0.217) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
RNF167 | SNV | Missense_Mutation | rs760638375 | c.844N>A | p.Glu282Lys | p.E282K | Q9H6Y7 | protein_coding | tolerated(0.24) | benign(0.022) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |
RNF167 | SNV | Missense_Mutation | rs775675214 | c.731G>A | p.Arg244Gln | p.R244Q | Q9H6Y7 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
RNF167 | SNV | Missense_Mutation | novel | c.487N>A | p.Val163Ile | p.V163I | Q9H6Y7 | protein_coding | tolerated(0.66) | benign(0.074) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |